Age at transplantation (years) | Mean ± SD | 9.3 ± 2.9 | |
---|---|---|---|
Post-transplant follow-up duration (months) | median (IQR) | 60 (36–93) | |
Original kidney disease | CAKUT | N (%) | 42 (50.6%) |
NONE CAKUT | N (%) | 41 (49.4%) | |
Family history of any kidney disease | N (%) | 6 (7.2%) | |
Patients required hemodialysis before transplantation | N (%) | 79 (95.2%) | |
Pre-epmptive kidney transplantation | N (%) | 4 (4.8%) | |
Hemodialysis duration (months) | median (IQR) | 12 (1–60) | |
Native nephrectomy | No | N (%) | 43 (51.8%) |
Unilateral | N (%) | 12 (14.5%) | |
Bilateral | N (%) | 28 (33.7%) | |
Cause of nephrectomy | Heavy proteinuria | N (%) | 17 (42.5%) |
Large polycystic kidney | N (%) | 2 (5%) | |
Pyelonephritic kidney | N (%) | 6 (15%) | |
Marked hydronephrosis | N (%) | 15 (37.5%) | |
Anthropometric measures at enrollment in the study | Weight (Kg) | Mean ± SD | 37 ± 11.9 |
Height (m) | Mean ± SD | 1.36 ± 0.17 | |
BMI (kg/m2) | Mean ± SD | 19.4 ± 4.5 | |
*CMV risk stratification | Low risk | N (%) | 8 (9.6%) |
Intermediate | N (%) | 70 (84.3%) | |
High risk | N (%) | 5 (6%) | |
Donor/recipient HLA mismatch | 4/6 | N (%) | 3 (3.6%) |
3/6 | N (%) | 50 (60.2%) | |
2/6 | N (%) | 25 (30.1%) | |
1/6 | N (%) | 3 (3.6%) | |
0/6 | N (%) | 2 (2.4%) | |
Antibody induction therapy | Basiliximab | N (%) | 43 (51.8%) |
ATG | N (%) | 40 (48.2%) | |
Preemptive PEX | N (%) | 15 (18.1%) | |
Maintenance IS other than TAC | MMF | N (%) | 82 (98.8%) |
Azathioprine | N (%) | 1 (1.2%) |